Vicor Technologies, Inc. (OTCBB: VCRT) – FDA Clears Vicor’s PD2i® Nonlinear Algorithm and Software To Measure Heart Rate Variability

Filed In: Vicor Technologies, VCRT, PD2i, FDA, Erwing Maneuvers, Medical Equipment, Diagnostic technology

Vicor Technologies, Inc. received 510(k) clearance in April 2011, from the U.S. Food and Drug Administration for its PD2i® nonlinear algorithm and software to be used as a measure of heart rate variability at rest and in response to controlled exercise and paced respiration (Ewing Maneuvers) in patients specifically undergoing cardiovascular disease testing.

The FDA approval has fully prepared the company’s transformation into a commercial company with a wider market reach.  Vicor Technologies is a medical diagnostics company focused on commercializing non-invasive diagnostic technology products based on its patented, proprietary point correlation dimension algorithm the PD2i ® Algorithm and software.

Vicor Company Website: http://www.vicortech.com/

Stockguru’s Profile on Vicor: http://stockguru.com//about/vcrt/

VCRT Disclosure: StockGuru entered into an investor relations consulting and market awareness contract with VCRT. We are also doing a video on ShareholderVision.com that will be released shortly.  The Company will pay us a total of seventy two hundred dollars and fifty thousand shares of restricted 144 stock for the period ending August 31, 2011. We still hold hold these shares.  To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable.  In early 2010, the Company paid us seventy two hundred dollars and fifty thousand shares of restricted 144 stock for a prior round of coverage that ended.   In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. StockGuru – 1601 Berwick Drive – McKinney, Texas 75070 – (469) 252-3031.